DOCSLIB.ORG

Potential Doping Substances Detected in Boosters in Poland

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Kwiatkowska, D1), Pokrywka, A1), Jarek, A1), Gorczyca, D 1) Potential doping substances detected in boosters in Poland 1)Department of Anti-Doping Research, Institute of Sport, Warsaw, Poland Abstract In 2003 the World Anti-Doping Agency (WADA) took responsibility for the List of substances and methods prohibited in sport (the Prohibited List). Since that moment the list has been regularly updated, and all changes, based mainly on scientific research, have been preceded by numerous consultations with representatives of the sport and medicine. By publishing a new version of the Prohibited List every year and by enlisting numerous examples of prohibited substances WADA fulfilled partly the need of publishing a complete list of prohibited substances. However, the Prohibited List still has an open character. In spite of the examples of prohibited substances or methods in particular groups, some additional substances, which are not located on the list but are characterized by “a similar chemical structure or similar biological effect(s)”, can be considered as doping. Introduction In recent years several well-known Polish athletes have personally found out what this definition means. In their urine samples 4-methyl-2-hexaneamine and beta- methylphenylethylamine were detected during the doping control. These substances, which were found also in dietary supplements, were not mentioned on the WADA Prohibited List at the time. However, both substances were recognized by WADA as banned in sport because of chemical similarity to the structure of tuaminoheptane and amphetamine. Potential doping substances can be also ingredients of boosters (legal highs, smarts, party pills). This work presents the results of analyses of several products from Polish market Materials and Methods The laboratory analysed 50 boosters available on the polish market. Samples were analysis by GC-MS in a SCAN mode (GC5890 – MS5975N, Agilent Technologies). GC program: 65°C WS2011 – POSTER 266 (2,00 min); 250 °C (15 °C/min, 6,00 min); 300 °C (20 °C/min, 4,00 min): Column: HP-5MS, 0.25 mm, ID 0.25 mm, 12 m. Injection volume 1 µL, Splitless. Standards were purchased from LGC Standards (Poland). Results and Discussion During the analysis laboratory found substances as follow (in alphabetical order): butylone (bk-MBDB; 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one) caffeine; (1,3,7-trimethyl-1H-purine-2,6(3H,7H)-dione) DBZP (dibenzylpiperazine;1,4-dibenzylpiperazine) ephedrine artefact (3,4-dimethyl-5-phenyl-1,3-oxazolidine) ethylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one) JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentylindol- 3-yl)methanone) MBZP (methylbenzylpiperazine;1-methyl-4-(phenylmethyl)piperazine;1-methyl-4- benzylpiperazine;1-benzyl-4-methylpiperazine) MDPV (methylenedioxypyrovalerone;1-(benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl) pentan-1-one) 4-MEC (4-methyl-N-ethylcathinone) metamfepramone (2-(dimethylamino)-1-phenylpropan-1-one) methedrone (bk-PMMA;1-(4-methoxyphenyl)-2-(methylamino)propan-1-one) methylone (bk-MDMA; (±)-2-methylamino-1-(3,4-methylenedioxyphenyl)propan-1-one) lidocaine (2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide) pFPP (para-Fluorophenylpiperazine1-(4-fluorophenyl)piperazine) 3-Phenyl-1H-pyrazole (5-phenyl-1H-pyrazole) pentylone (bk-MBDP; (±)-1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one) TFMPP (trifluoromethylphenylpiperazine;1-[3-(trifluoromethyl) phenyl]piperazine) All substances detected by the Warsaw Anti-Doping Laboratory may by reported as potential doping substances. The following substances for which the structure and MS spectrum is shown match the definition of doping substances due to their chemical similarity to items mentioned in the PROHIBITED LIST. Many other compounds found also could be doping substances eg methcathinone derivatives etc.. WS2011 – POSTER 267 1) class S6 STIMULANTS - DBZP (dibenzylpiperazine;1,4-dibenzylpiperazine) Abundance Scan 1876 (13.021 min): al10-3278.D\data.ms (-) 55000 91.0 50000 45000 40000 N 35000 30000 N 25000 20000 15000 120.1 175.1 10000 65.0 266.1 5000 146.0 42.0 194.0 238.1 298.1 0 40 60 80 100 120 140 160 180 200 220 240 260 280 300 m/z--> - pFPP (para-Fluorophenylpiperazine1-(4-fluorophenyl)piperazine) Abundance Scan 760 (7.425 min): d10-3232.D\ data.ms (-675) (-) 138.1 8000 7500 7000 6500 6000 NH 5500 5000 N 4500 4000 3500 3000 180.1 2500 2000 F 1500 1000 95.2 500 223.2 354.8 430.8 63.3 269.1 318.2 463.2 0 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 460 m/ z--> - MBZP (methylbenzylpiperazine;1-methyl-4-(phenylmethyl)piperazine;1-methyl-4- benzylpiperazine;1-benzyl-4-methylpiperazine) Abundance Scan 1038 (8.137 min): al10-3274.D\data.ms (-) 91.1 1000000 900000 800000 N 700000 600000 190.1 N 500000 119.1 400000 56.1 300000 200000 146.1 100000 220.7 282.9 327.0 415.8 0 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 m/z--> WS2011 – POSTER 268 - TFMPP (trifluoromethylphenylpiperazine;1-[3-(trifluoromethyl) phenyl]piperazine) Abundance Scan 1348 (9.944 min): al10-3232.D\ data.ms (-) 188.0 17000 16000 15000 14000 NH 13000 12000 11000 F C N 10000 3 9000 8000 7000 6000 5000 168.9 4000 230.2 3000 144.9 2000 56.0 83.5 211.0 1000 41.1 127.0 100.0 0 40 60 80 100 120 140 160 180 200 220 240 m/ z--> - MDPV (methylenedioxypyrovalerone;1-(benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1- yl) pentan-1-one) Abundance Scan 1859 (12.922 min): al10-3239.D\data.ms (-1867) (-) 126.1 8000000 7000000 O 6000000 O N 5000000 4000000 O 3000000 2000000 1000000 65.0 42.1 96.0 149.0 176.9 204.1 232.1 256.0 274.1 0 40 60 80 100 120 140 160 180 200 220 240 260 280 m/ z--> 2) class S8 CANNABINOIDS - JWH-081 (4-methoxynaphthalen- 1-yl- (1-pentylindol- 3-yl)methanone) Abundance Scan 3976 (25.262 min): al10-3244.D\ data.ms (-) 3500000 371.2 3000000 2500000 2000000 314.1 N 1500000 214.1 185.1 1000000 144.0 43.1 114.1 500000 285.1 254.1 77.0 405.0 450.9 0 40 60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400 420 440 m/z--> References 1. Perrenoud L, Saugy M, Saudan C. (2009) Detection in urine of 4-methyl-2-hexaneamine, a doping agent. J Chromatogr B, 877, 3767-3770. WS2011 – POSTER 269 .
Recommended publications
  • The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    The 2021 List of Pharmacological Classes of Doping Agents and Doping Methods

    BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 1 von 23 The 2021 list of pharmacological classes of doping agents and doping methods www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 2 von 23 www.ris.bka.gv.at BGBl. III - Ausgegeben am 8. Jänner 2021 - Nr. 1 3 von 23 THE 2021 PROHIBITED LIST WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE 1 January 2021 Introduction The Prohibited List is a mandatory International Standard as part of the World Anti-Doping Program. The List is updated annually following an extensive consultation process facilitated by WADA. The effective date of the List is 1 January 2021. The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. Below are some terms used in this List of Prohibited Substances and Prohibited Methods. Prohibited In-Competition Subject to a different period having been approved by WADA for a given sport, the In- Competition period shall in principle be the period commencing just before midnight (at 11:59 p.m.) on the day before a Competition in which the Athlete is scheduled to participate until the end of the Competition and the Sample collection process. Prohibited at all times This means that the substance or method is prohibited In- and Out-of-Competition as defined in the Code. Specified and non-Specified As per Article 4.2.2 of the World Anti-Doping Code, “for purposes of the application of Article 10, all Prohibited Substances shall be Specified Substances except as identified on the Prohibited List.
  • (CD-P-PH/PHO) Report Classification/Justifica

    (CD-P-PH/PHO) Report Classification/Justifica

    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST

    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
  • Final Decisions & Reasons for Decisions by Delegates of the Secretary to the Department of Health

    Final Decisions & Reasons for Decisions by Delegates of the Secretary to the Department of Health

    Final decisions & reasons for decisions by delegates of the Secretary to the Department of Health 29 June 2017 (ACMS and ACCS meetings – March 2017) Notice under subsections 42ZCZS/42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations) The delegates of the Secretary to the Department of Health hereby give notice of delegates’ final decisions for amending the Poisons Standard (commonly referred to as the Standard for the Uniform Scheduling of Medicines and Poisons - SUSMP) under subsections 42ZCZS/42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations). This notice also provides the reasons for each decision and the date of effect (implementation date) of the decision. The delegates’ final decisions and reasons relate to: · scheduling proposals initially referred to the March 2017 meeting of the Advisory Committee on Medicines Scheduling (ACMS#20); · scheduling proposals initially referred to the March 2017 Joint meeting of the Advisory Committees on Chemicals and Medicines Scheduling (ACCS-ACMS#15); · scheduling proposals initially referred to the March 2017 meeting of the Advisory Committee on Chemicals Scheduling (ACCS#19); and · scheduling proposals considered as delegate-only matters, i.e. not referred to an expert advisory committee. Scheduling proposals referred to the expert advisory committees. Pre-meeting public notices On 22 December 2016 and 3 February 2017, under subsection 42ZCZK of the Therapeutic Goods Regulations 1990 (the Regulations), the delegate published pre-meeting public notices on the TGA website which specified the proposed amendments to the current Poisons Standard. The notices also invited public comment on the scheduling proposals referred to the expert advisory committees. The pre-meeting consultation periods were open for public comment for 20 business days and closed on 10 February 2017 and 3 March 2017, respectively.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • Prohibited Substances List

    Prohibited Substances List

    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
  • World Anti-Doping Code

    World Anti-Doping Code

    BGBl. III - Ausgegeben am 31. Jänner 2007 - Nr. 12 1 von 9 THE 2007 PROHIBITED LIST WORLD ANTI-DOPING CODE DATE OF ENTRY INTO FORCE : 1 JANUARY 2007 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α-androst-1-ene-3,17- dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4- diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4- eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α- methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β- ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol); methyldienolone (17β-hydroxy- 17α-methylestra-4,9-dien-3-one); methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst- 1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltrienolone (17β-hydroxy-17α-methylestra-4,9,11-trien-3-one); methyltestosterone; mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol ([3,2-c]pyrazole-5α-etioallocholane-17β-tetrahydropyranol); quinbolone; stanozolol; stenbolone; 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one); tetrahydrogestrinone (18a-homo-pregna-4,9,11-trien-17β-ol-3-one); trenbolone and other substances with a similar chemical structure or similar biological effect(s).
  • 16.19.20 Nmac 1 Title 16 Occupational And

    16.19.20 Nmac 1 Title 16 Occupational And

    TITLE 16 OCCUPATIONAL AND PROFESSIONAL LICENSING CHAPTER 19 PHARMACISTS PART 20 CONTROLLED SUBSTANCES 16.19.20.1 ISSUING AGENCY: Regulation and Licensing Department - Board of Pharmacy. [16.19.20.1 NMAC - Rp 16.19.20.1 NMAC, 06-26-2018] 16.19.20.2 SCOPE: All persons or entities that manufacture, distribute, dispense, administer, prescribe, deliver, analyze, or conduct research using controlled substances. [16.19.20.2 NMAC - Rp 16.19.20.2 NMAC, 06-26-2018] 16.19.20.3 STATUTORY AUTHORITY: Section 30-31-11 of the Controlled Substances Act, 30-31-1 through 30-31-42 NMSA 1978, authorizes the board of pharmacy to promulgate regulations and charge reasonable fees for the registration and control of the manufacture, distribution and dispensing of controlled substances. [16.19.20.3 NMAC - Rp 16.19.20.3 NMAC, 06-26-2018] 16.19.20.4 DURATION: Permanent. [16.19.20.4 NMAC - Rp 16.19.20.4 NMAC, 06-26-2018] 16.19.20.5 EFFECTIVE DATE: June 26, 2018, unless a different date is cited at the end of a section. [16.19.20.5 NMAC - Rp 16.19.20.5 NMAC, 06-26-2018] 16.19.20.6 OBJECTIVE: The objective of Part 20 of Chapter 19 is to protect the public health and welfare of the citizens of New Mexico by controlling and monitoring access to controlled substances and to give notice of the board’s designation of particular substances as controlled substances. [16.19.20.6 NMAC - Rp 16.19.20.6 NMAC, 06-26-2018] 16.19.20.7 DEFINITIONS: [RESERVED] [16.19.20.7 NMAC - Rp 16.19.20.7 NMAC, 06-26-2018] 16.19.20.8 REGISTRATION REQUIREMENTS: Persons required to register: A.
  • Mass Spectral, Infrared and Chromatographic Studies on Designer Drugs of the Piperazine Class by Karim M. Hafiz Abdel-Hay a Diss

    Mass Spectral, Infrared and Chromatographic Studies on Designer Drugs of the Piperazine Class by Karim M. Hafiz Abdel-Hay a Diss

    Mass Spectral, Infrared and Chromatographic Studies on Designer Drugs of the Piperazine Class by Karim M. Hafiz Abdel-Hay A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of the requirements for the degree of Doctor of Philosophy Auburn, Alabama May 7, 2012 Approved by C. Randall Clark, Chair, Professor of Pharmacal Sciences Jack DeRuiter, Professor of Pharmacal Sciences Forrest Smith, Associate Professor of Pharmacal Sciences Angela Calderon, Assistant Professor of Pharmacal Sciences Abstract The controlled drug 3,4-methylenedioxybenzylpiperazine (3,4-MDBP) has regioisomeric and isobaric substances of mass equivalence, which have similar analytical properties and thus the potential for misidentification. The direct regioisomers of 3,4-MDBP include the 2,3- methylenedioxy substitution pattern and the indirect regioisomers include the three ring substituted methoxybenzoylpiperazines. The ethoxy and methoxymethyl ring substituted benzylpiperazines constitute the major category of isobaric substances evaluated in this study. The direct and indirect regioisomers of 3,4-MDBP and also isobaric substances related to MDBP were synthesized and compared to 3,4-MDBP by using gas chromatographic and spectrophotometric techniques. The GC-MS studies of the direct regioisomers and isobaric substances of 3,4-MDBP indicated that they can not be easily differentiated by mass spectrometry. The synthesized compounds were converted to their perfluoroacyl derivatives, trifluoroacetyl (TFA), pentafluoropropionyl amides (PFPA) and heptafluorobutryl amides (HFBA), in an effort to individualize their mass spectra and to improve chromatographic resolution. Derivatized 3,4-MDBP was not distingushed from its derivatized regioisomers or isobars using mass spectrometry. No unique fragment ions were observed for the various regioisomeric and the isobaric compounds.
  • 2008 Prohibited List

    2008 Prohibited List

    The World Anti-Doping Code THE 2008 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2008 The Prohibited List 2008 September 22, 2007 THE 2008 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 2008 The use of any drug should be limited to medically justified indications SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3β,17β-diol ); 1-androstendione (5α- androst-1-ene-3,17-dione); bolandiol (19-norandrostenediol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazole); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en- 17β-ol); drostanolone; ethylestrenol (19-nor-17α-pregn-4-en-17-ol); fluoxymesterone; formebolone; furazabol (17β-hydroxy-17α-methyl-5α- androstano[2,3-c]-furazan); gestrinone; 4-hydroxytestosterone (4,17β- dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metenolone; methandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); methandriol; methasterone (2α, 17α-dimethyl-5α-androstane-3-one-17β-ol);
  • Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority

    Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority

    Chapter 8 – Alcohol and Drug Abuse Subchapter 9 Regulated Drug Rule 1.0 Authority This rule is established under the authority of 18 V.S.A. §§ 4201 and 4202 which authorizes the Vermont Board of Health to designate regulated drugs for the protection of public health and safety. 2.0 Purpose This rule designates drugs and other chemical substances that are illegal or judged to be potentially fatal or harmful for human consumption unless prescribed and dispensed by a professional licensed to prescribe or dispense them, and used in accordance with the prescription. The rule restricts the possession of certain drugs above a specified quantity. The rule also establishes benchmark unlawful dosages for certain drugs to provide a baseline for use by prosecutors to seek enhanced penalties for possession of higher quantities of the drug in accordance with multipliers found at 18 V.S.A. § 4234. 3.0 Definitions 3.1 “Analog” means one of a group of chemical components similar in structure but different with respect to elemental composition. It can differ in one or more atoms, functional groups or substructures, which are replaced with other atoms, groups or substructures. 3.2 “Benchmark Unlawful Dosage” means the quantity of a drug commonly consumed over a twenty-four hour period for any therapeutic purpose, as established by the manufacturer of the drug. Benchmark Unlawful dosage is not a medical or pharmacologic concept with any implication for medical practice. Instead, it is a legal concept established only for the purpose of calculating penalties for improper sale, possession, or dispensing of drugs pursuant to 18 V.S.A.
  • Alphabetical Listing of ATC Drugs & Codes

    Alphabetical Listing of ATC Drugs & Codes

    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04